Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitab...

nork Wohl, David, Clarke, Amanda, Maggiolo, Franco, Garner, Will, Laouri, Marianne, Martin, Hal, Quirk, Erin
Argitaratua izan da Patient (2018)

Lack of Clinically Relevant Effect of Bictegravir (BIC, B) on Metformin (MET) Pharmacokinetics (PK) and Pharmacodynamics (PD)

nork Custodio, Joseph, West, Steve, Yu, Amanda, Martin, Hal, Graham, Hiba, Quirk, Erin, Kearney, Brian
Argitaratua izan da Open Forum Infect Dis (2017)

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults

nork Gallant, Joel E., Thompson, Melanie, DeJesus, Edwin, Voskuhl, Gene W., Wei, Xuelian, Zhang, Heather, White, Kirsten, Cheng, Andrew, Quirk, Erin, Martin, Hal
Argitaratua izan da J Acquir Immune Defic Syndr (2017)

A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination

nork Sax, Paul E, Dejesus, Edwin, Crofoot, Gordon, Ward, Douglas, Benson, Paul, Wei, Lilian, White, Kirsten, Collins, Sean, Martin, Hal, Cheng, Andrew, Quirk, Erin
Argitaratua izan da Open Forum Infect Dis (2017)

Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without Adjuvants

nork Quirk, Erin K., Brown, Elizabeth L., Leavitt, Randi Y., Mogg, Robin, Mehrotra, Devan V., Evans, Robert K., DiNubile, Mark J., Robertson, Michael N.
Argitaratua izan da Open Forum Infect Dis (2014)

Erratum to: Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

nork Andreatta, Kristen, Willkom, Madeleine, Martin, Ross, Chang, Silvia, Wei, Lilian, Liu, Hui, Liu, Ya-Pei, Graham, Hiba, Quirk, Erin, Martin, Hal, White, Kirsten L
Argitaratua izan da J Antimicrob Chemother (2019)

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

nork Andreatta, Kristen, Willkom, Madeleine, Martin, Ross, Chang, Silvia, Wei, Lilian, Liu, Hui, Liu, Ya-Pei, Graham, Hiba, Quirk, Erin, Martin, Hal, White, Kirsten L
Argitaratua izan da J Antimicrob Chemother (2019)

Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy

nork Chaparro, Juan, Reeds, Dominic N., Wen, Weidong, Xueping, E., Klein, Samuel, Semenkovich, Clay F., Bae, Kyongtae T., Quirk, Erin K., Powderly, William G., Yarasheski, Kevin E., Li, Ellen
Argitaratua 2005

Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks

nork Acosta, Rima K., Willkom, Madeleine, Martin, Ross, Chang, Silvia, Wei, Xuelian, Garner, William, Lutz, Justin, Majeed, Sophia, SenGupta, Devi, Martin, Hal, Quirk, Erin, White, Kirsten L.
Argitaratua izan da Antimicrob Agents Chemother (2019)

Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults

nork Harro, Clayton, Sun, Xiao, Stek, Jon E., Leavitt, Randi Y., Mehrotra, Devan V., Wang, Fubao, Bett, Andrew J., Casimiro, Danilo R., Shiver, John W., DiNubile, Mark J., Quirk, Erin
Argitaratua 2009

Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults

nork Harro, Clayton, Sun, Xiao, Stek, Jon E., Leavitt, Randi Y., Mehrotra, Devan V., Wang, Fubao, Bett, Andrew J., Casimiro, Danilo R., Shiver, John W., DiNubile, Mark J., Quirk, Erin
Argitaratua 2010

LB4. A Phase 3, Randomized, Controlled Clinical Trial of Bictegravir in a Fixed-Dose Combination, B/F/TAF, vs. ABC/DTG/3TC in Treatment-Naïve Adults at Week 96

nork Wohl, David A, Yazdanpanah, Yazdan, Baumgarten, Axel, Clarke, Amanda, Thompson, Melanie, Brinson, Cynthia, Hagins, Debbie, Ramgopal, Moti, Antinori, Andrea, Wei, Xuelian, White, Kirsten, Collins, Sean, Cheng, Andrew, Quirk, Erin, Martin, Hal
Argitaratua izan da Open Forum Infect Dis (2018)

Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologi...

nork Daar, Eric, DeJesus, Edwin, Ruane, Peter, Crofoot, Gordon, Oguchi, Godson, Creticos, Catherine, Rockstroh, Jurgen K, Molina, Jean-Michel, Koenig, Ellen, Liu, Ya-Pei, Andreatta, Kristen, Graham, Hiba, Cheng, Andrew, Martin, Hal, Quirk, Erin
Argitaratua izan da Open Forum Infect Dis (2017)

Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults

nork Nicholson, Ouzama, DiCandilo, Fay, Kublin, James, Sun, Xiao, Quirk, Erin, Miller, Michelle, Gray, Glenda, Pape, Jean, Robertson, Michael N., Mehrotra, Devan V., Self, Steven, Turner, Katherine, Sanchez, Jorge, Pitisuttithum, Punnee, Duerr, Ann, Dubey, Sheri, Kierstead, Lisa, Casimiro, Danilo, Hammer, Scott M.
Argitaratua 2011